FDMT's lead candidate, 4D-150, is being developed for the treatment of wet AMD, a leading cause of vision loss in older adults. The company has reported data from its Phase 1/2 and 2b PRISM trials, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback